Immune Design Corp. (IMDZ) Trading Up 2.3%
Immune Design Corp. (NASDAQ:IMDZ) was up 2.3% during trading on Monday . The company traded as high as $7.24 and last traded at $7.04, with a volume of 71,626 shares. The stock had previously closed at $6.88.
A number of equities research analysts have recently commented on IMDZ shares. Leerink Swann reissued a “buy” rating on shares of Immune Design Corp. in a research note on Friday, June 10th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Immune Design Corp. in a report on Wednesday, May 11th. Zacks Investment Research downgraded Immune Design Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Jefferies Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Immune Design Corp. in a report on Wednesday, May 11th. Finally, Cowen and Company reaffirmed an “outperform” rating on shares of Immune Design Corp. in a report on Wednesday, April 27th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $24.00.
The firm’s 50-day moving average price is $9.37 and its 200-day moving average price is $11.67. The stock’s market cap is $141.27 million.
Immune Design Corp. (NASDAQ:IMDZ) last issued its earnings results on Tuesday, May 10th. The company reported ($0.61) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.01. On average, analysts forecast that Immune Design Corp. will post ($2.70) EPS for the current year.
Other large investors have recently modified their holdings of the company. Jennison Associates LLC raised its stake in shares of Immune Design Corp. by 0.4% in the fourth quarter. Jennison Associates LLC now owns 203,452 shares of the company’s stock worth $4,085,000 after buying an additional 769 shares during the period. Oxford Asset Management purchased a new stake in shares of Immune Design Corp. during the fourth quarter worth $1,166,000. Finally, Jennison Associates raised its stake in shares of Immune Design Corp. by 0.6% in the third quarter. Jennison Associates now owns 202,683 shares of the company’s stock worth $2,473,000 after buying an additional 1,224 shares during the period.
Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.